Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
BACKGROUND: Second-line chemotherapy for patients with oesophagogastric adenocarcinoma refractory to platinum and fluoropyrimidines has not shown benefits in health-related quality of life (HRQoL). We assessed whether the addition of docetaxel to active symptom control alone can improve survival and...
Main Authors: | Ford, Hugo, Marshall, Andrea, Bridgewater, John A., Janowitz, Tobias, Coxon, Fareeda, Wadsley, Jonathan, Mansoor, Wasat, Fyfe, David, Madhusudan, Srinivasan, Middleton, Gary, Swinson, Daniel, Falk, Stephen, Chau, Ian, Cunningham, David, Kareclas, Paula, Cook, Natalie, Blazeby, Jane M., Dunn, Janet A. |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2014
|
Online Access: | http://eprints.nottingham.ac.uk/43067/ http://eprints.nottingham.ac.uk/43067/ http://eprints.nottingham.ac.uk/43067/ http://eprints.nottingham.ac.uk/43067/1/lancet_oncology_2014_2.pdf |
Similar Items
-
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
by: Waddell, Tom, et al.
Published: (2013) -
Effects of hunting on cougar spatial organization
by: Maletzke, Benjamin T, et al.
Published: (2014) -
Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
by: Tebbutt, N C, et al.
Published: (2013) -
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial
by: Tebbutt, Niall C, et al.
Published: (2016) -
Seasonal Foraging Ecology of Non-Migratory Cougars in a System with Migrating Prey
by: Elbroch, L. Mark, et al.
Published: (2013)